STAT Plus: Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future
Before it even started, ASCO 2020 was one for the books. Held virtually for the first time in its history instead of at Chicago’s massive McCormick Place conference center, the American Society of Clinical Oncology’s big meeting also shrank from five days to three last weekend.
After following ASCO news from afar, STAT’s Adam Feuerstein on Wednesday continued in that vein, hosting a virtual chat with three noted oncologists to get their take on the future of cancer therapy. After big news from AstraZeneca in lung cancer, Johnson & Johnson in multiple myeloma, and Allogene in off-the-shelf gene therapy, they paused to reflect on their field — and ASCO 2021. Here are some of their observations:
Continue to STAT Plus to read the full story…
